LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASES

[1]  W. Watson,et al.  Albumin standards and the measurement of serum albumin with bromcresol green. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[2]  E. Vignon,et al.  Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. , 1982, The Journal of clinical endocrinology and metabolism.

[3]  A. Chantraine,et al.  Parenteral diphosphonates for treating malignant hypercalcemia , 1981, Cancer.

[4]  E. Siris,et al.  Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. , 1981, Annals of internal medicine.

[5]  F. Preston,et al.  EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASE , 1980, The Lancet.

[6]  E. Vignon,et al.  Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. , 1980, The Journal of clinical investigation.

[7]  E. Siris,et al.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. , 1980, The New England journal of medicine.

[8]  O. Bijvoet,et al.  INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.) , 1979, The Lancet.

[9]  G. Mundy,et al.  Direct resorption of bone by human breast cancer cells in vitro , 1978, Nature.

[10]  G. Mundy.  Calcium and cancer. , 1978, Life sciences.

[11]  H. Fleisch,et al.  The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. , 1978, The Biochemical journal.

[12]  M. Potsaid,et al.  Improved method for quantitative bone scanning. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  C. Galasko.  Mechanisms of bone destruction in the development of skeletal metastases , 1976, Nature.

[14]  H. Fleisch,et al.  Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects. , 1975, Clinical orthopaedics and related research.

[15]  G. Mundy,et al.  Evidence for the secretion of an osteoclast stimulating factor in myeloma. , 1974, The New England journal of medicine.

[16]  K. Kivirikko,et al.  Modifications of a specific assay for hydroxyproline in urine. , 1967, Analytical biochemistry.

[17]  B. A. Goddard,et al.  Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging. , 1981, The British journal of radiology.

[18]  J. Koeller,et al.  Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation. , 1981, Cancer treatment reports.

[19]  T. Yoneda,et al.  Osteoclast activating factor : its role in myeloma and other types of hypercalcaemia of malignancy , 1980 .

[20]  D. Hosking,et al.  Treatment of Paget's disease with combined calcitonin and diphosphonate (EHDP) , 1978 .